EsopH's unique mode of action provides safe alternative to Proton Pump Inhibitors
MARKHAM, ON, June 28, 2018 /CNW/ - Exzell Pharma Inc. is pleased to announce the Health Canada approval of EsopH™ an innovative oral therapy for stomach acid induced heartburn. EsopH™, which is packaged in single-dose drinkable liquid sachets, protects patients from symptoms of Gastroesophageal Reflux Disease (GERD), by creating a barrier on the surface of the patient's esophagus. Made entirely of naturally sourced ingredients, EsopH™ can be used in place of, or as a complement to prescription therapies.
Approximately 20% of North Americans suffer from GERD, according to the National Institute of Diabetes and Digestive and Kidney Diseases. The current standard of care is prescription proton pump inhibitors (PPIs), which, when taken orally, block the enzyme that controls stomach acid production. PPIs may be poorly tolerated with some patients experiencing diarrhea, headaches, flatulence, abdominal pain, or constipation. PPIs also have known interactions with many common drug therapies including clopidogrel (Plavix), warfarin, and naproxen (Aleve).
The approval of EsopH™ creates an effective and safe option for patients seeking a therapeutic alternative for GERD. EsopH™ has a unique mode of action, and it does not require a prescription. Canadian patients will now have access to this innovative therapy that has already brought value to European GERD sufferers.
About Exzell Pharma
Exzell Pharma Inc. was founded in 2014, as an emerging OTC and prescription pharmaceutical company serving the Canadian market. In addition to EsopH, Exzell products include Swiss Natural supplements, Myoflex, a leading OTC topical for pain, and Ozonol a leading first aid ointment. The executive team has a long history delivering value to Canadians, having previously founded and sold Medical Futures Incorporated.